Chromadex Net Receivables vs Other Current Liab Analysis

CDXC Stock

USD 7.44 0.19 2.49%

Chromadex Corp financial indicator trend analysis is way more than just evaluating Chromadex Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Chromadex Corp is a good investment. Please check the relationship between Chromadex Corp Net Receivables and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.

Net Receivables vs Other Current Liab

Net Receivables vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Chromadex Corp Net Receivables account and Other Current Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Chromadex Corp's Net Receivables and Other Current Liab is 0.57. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Chromadex Corp, assuming nothing else is changed. The correlation between historical values of Chromadex Corp's Net Receivables and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Chromadex Corp are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Net Receivables i.e., Chromadex Corp's Net Receivables and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.57

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Other Current Liab

Most indicators from Chromadex Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Chromadex Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.At present, Chromadex Corp's Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Interest Expense	55K	3K	3.5K	3.3K
Depreciation And Amortization	1.6M	1.9M	1.7M	863.7K

Interest Expense Depreciation And Amortization

Chromadex Corp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Other Current Assets
Total Assets		0.39	0.75	0.94	-0.88	-0.75	0.77	0.9	0.89	0.87	0.9	0.78	-0.03	0.87	0.62	0.8	0.81	0.74	0.65	0.93	0.72	-0.08	0.74	0.83	-0.16	0.66
Short Long Term Debt Total	0.39		0.49	0.16	-0.08	-0.51	0.54	0.2	0.38	0.08	0.2	0.4	0.46	0.51	0.78	0.62	0.46	0.6	0.41	0.35	-0.09	0.42	0.32	0.53	-0.29	0.57
Total Current Liabilities	0.75	0.49		0.54	-0.6	-0.96	0.87	0.67	0.76	0.56	0.67	0.62	0.08	0.87	0.84	0.87	0.96	0.99	0.92	0.84	0.44	0.03	0.94	0.81	-0.19	0.8
Total Stockholder Equity	0.94	0.16	0.54		-0.95	-0.54	0.53	0.94	0.76	0.89	0.94	0.7	-0.12	0.67	0.36	0.55	0.64	0.51	0.49	0.89	0.78	-0.16	0.6	0.64	-0.06	0.48
Net Debt	-0.88	-0.08	-0.6	-0.95		0.58	-0.48	-0.99	-0.7	-0.87	-0.99	-0.55	0.15	-0.61	-0.37	-0.48	-0.69	-0.55	-0.58	-0.92	-0.81	0.19	-0.7	-0.57	0.09	-0.49
Retained Earnings	-0.75	-0.51	-0.96	-0.54	0.58		-0.82	-0.66	-0.79	-0.53	-0.66	-0.62	-0.09	-0.88	-0.89	-0.87	-0.99	-0.98	-0.93	-0.83	-0.35	-0.04	-0.94	-0.85	0.24	-0.89
Accounts Payable	0.77	0.54	0.87	0.53	-0.48	-0.82		0.53	0.82	0.61	0.53	0.64	0.09	0.93	0.75	0.95	0.79	0.87	0.67	0.69	0.49	0.04	0.71	0.87	-0.21	0.65
Cash	0.9	0.2	0.67	0.94	-0.99	-0.66	0.53		0.72	0.84	1.0	0.58	-0.09	0.65	0.48	0.54	0.76	0.64	0.66	0.96	0.76	-0.12	0.76	0.62	-0.12	0.57
Non Current Assets Total	0.89	0.38	0.76	0.76	-0.7	-0.79	0.82	0.72		0.83	0.72	0.7	-0.15	0.85	0.71	0.82	0.81	0.78	0.65	0.81	0.67	-0.18	0.71	0.95	-0.16	0.73
Non Currrent Assets Other	0.87	0.08	0.56	0.89	-0.87	-0.53	0.61	0.84	0.83		0.84	0.59	-0.29	0.64	0.39	0.58	0.61	0.53	0.43	0.8	0.9	-0.31	0.57	0.7	-0.11	0.4
Cash And Short Term Investments	0.9	0.2	0.67	0.94	-0.99	-0.66	0.53	1.0	0.72	0.84		0.58	-0.09	0.65	0.48	0.54	0.76	0.64	0.66	0.96	0.76	-0.12	0.76	0.62	-0.12	0.57
Net Receivables	0.78	0.4	0.62	0.7	-0.55	-0.62	0.64	0.58	0.7	0.59	0.58		-0.06	0.71	0.51	0.72	0.66	0.61	0.55	0.72	0.38	-0.09	0.57	0.73	-0.04	0.59
Common Stock Total Equity	-0.03	0.46	0.08	-0.12	0.15	-0.09	0.09	-0.09	-0.15	-0.29	-0.09	-0.06		0.23	0.21	0.12	0.06	0.13	-0.01	-0.03	-0.38	0.99	-0.11	-0.14	0.41	0.07
Common Stock Shares Outstanding	0.87	0.51	0.87	0.67	-0.61	-0.88	0.93	0.65	0.85	0.64	0.65	0.71	0.23		0.76	0.94	0.87	0.87	0.72	0.79	0.46	0.18	0.76	0.86	-0.06	0.72
Non Current Liabilities Total	0.62	0.78	0.84	0.36	-0.37	-0.89	0.75	0.48	0.71	0.39	0.48	0.51	0.21	0.76		0.83	0.85	0.92	0.79	0.66	0.16	0.17	0.74	0.83	-0.35	0.89
Inventory	0.8	0.62	0.87	0.55	-0.48	-0.87	0.95	0.54	0.82	0.58	0.54	0.72	0.12	0.94	0.83		0.84	0.89	0.73	0.72	0.37	0.06	0.74	0.9	-0.23	0.75
Other Stockholder Equity	0.81	0.46	0.96	0.64	-0.69	-0.99	0.79	0.76	0.81	0.61	0.76	0.66	0.06	0.87	0.85	0.84		0.96	0.94	0.9	0.44	0.01	0.96	0.84	-0.2	0.88
Total Liab	0.74	0.6	0.99	0.51	-0.55	-0.98	0.87	0.64	0.78	0.53	0.64	0.61	0.13	0.87	0.92	0.89	0.96		0.91	0.82	0.37	0.08	0.91	0.84	-0.24	0.85
Property Plant And Equipment Gross	0.65	0.41	0.92	0.49	-0.58	-0.93	0.67	0.66	0.65	0.43	0.66	0.55	-0.01	0.72	0.79	0.73	0.94	0.91		0.81	0.27	-0.07	0.96	0.71	-0.25	0.85
Total Current Assets	0.93	0.35	0.84	0.89	-0.92	-0.83	0.69	0.96	0.81	0.8	0.96	0.72	-0.03	0.79	0.66	0.72	0.9	0.82	0.81		0.67	-0.07	0.87	0.76	-0.15	0.73
Intangible Assets	0.72	-0.09	0.44	0.78	-0.81	-0.35	0.49	0.76	0.67	0.9	0.76	0.38	-0.38	0.46	0.16	0.37	0.44	0.37	0.27	0.67		-0.39	0.47	0.5	-0.11	0.15
Common Stock	-0.08	0.42	0.03	-0.16	0.19	-0.04	0.04	-0.12	-0.18	-0.31	-0.12	-0.09	0.99	0.18	0.17	0.06	0.01	0.08	-0.07	-0.07	-0.39		-0.16	-0.17	0.46	0.03
Other Current Liab	0.74	0.32	0.94	0.6	-0.7	-0.94	0.71	0.76	0.71	0.57	0.76	0.57	-0.11	0.76	0.74	0.74	0.96	0.91	0.96	0.87	0.47	-0.16		0.74	-0.26	0.79
Property Plant And Equipment Net	0.83	0.53	0.81	0.64	-0.57	-0.85	0.87	0.62	0.95	0.7	0.62	0.73	-0.14	0.86	0.83	0.9	0.84	0.84	0.71	0.76	0.5	-0.17	0.74		-0.33	0.84
Current Deferred Revenue	-0.16	-0.29	-0.19	-0.06	0.09	0.24	-0.21	-0.12	-0.16	-0.11	-0.12	-0.04	0.41	-0.06	-0.35	-0.23	-0.2	-0.24	-0.25	-0.15	-0.11	0.46	-0.26	-0.33		-0.35
Other Current Assets	0.66	0.57	0.8	0.48	-0.49	-0.89	0.65	0.57	0.73	0.4	0.57	0.59	0.07	0.72	0.89	0.75	0.88	0.85	0.85	0.73	0.15	0.03	0.79	0.84	-0.35

Click cells to compare fundamentals

Chromadex Corp Account Relationship Matchups

Chromadex Corp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	40.2M	38.4M	57.8M	54.1M	55.0M	28.4M
Short Long Term Debt Total	1.7M	1.6M	4.7M	4.3M	3.3M	1.7M
Total Current Liabilities	15.1M	16.5M	17.6M	17.9M	20.6M	21.7M
Total Stockholder Equity	20.4M	16.4M	31.7M	28.7M	28.5M	15.9M
Net Debt	(17.1M)	(14.9M)	(23.3M)	(16.0M)	(23.9M)	(22.7M)
Retained Earnings	(121.9M)	(141.8M)	(169.0M)	(185.5M)	(190.5M)	(180.9M)
Accounts Payable	9.6M	9.4M	10.4M	9.7M	10.2M	5.6M
Cash	18.8M	16.5M	28.0M	20.2M	27.3M	28.7M
Non Current Assets Total	6.7M	6.1M	8.9M	7.5M	5.4M	4.3M
Non Currrent Assets Other	762K	625K	723K	497K	383K	354.2K
Cash And Short Term Investments	18.8M	16.5M	28.0M	20.2M	27.3M	28.7M
Net Receivables	2.2M	2.7M	5.2M	8.5M	5.2M	3.2M
Common Stock Total Equity	60K	62K	68K	74K	85.1K	69.4K
Common Stock Shares Outstanding	57.1M	61.1M	67.2M	69.7M	75.0M	43.1M
Liabilities And Stockholders Equity	40.2M	38.4M	57.8M	54.1M	55.0M	28.4M
Non Current Liabilities Total	4.7M	5.5M	8.5M	7.5M	5.9M	6.2M
Inventory	11.5M	11.7M	13.6M	14.7M	14.5M	7.4M
Other Stockholder Equity	142.3M	158.2M	200.6M	214.1M	218.8M	229.8M
Total Liab	19.8M	21.9M	26.1M	25.4M	26.5M	27.8M
Property Plant And Equipment Gross	4.7M	4.4M	7.4M	6.3M	9.9M	10.4M
Total Current Assets	33.5M	32.2M	48.9M	46.6M	49.5M	52.0M
Accumulated Other Comprehensive Income	(2.1M)	0.0	(3K)	(2K)	(4K)	(4.2K)
Intangible Assets	1.3M	1.1M	857K	671K	510K	694.8K
Common Stock	60K	62K	68K	74K	75K	70.5K
Other Current Liab	4.4M	5.5M	5.4M	5.9M	8.1M	8.5M
Property Plant And Equipment Net	4.7M	4.4M	7.4M	6.3M	4.5M	3.2M
Current Deferred Revenue	169K	278K	161K	157K	195K	263.8K
Other Current Assets	996K	1.3M	3.7M	3.0M	2.5M	2.6M
Short Term Debt	853K	1.2M	1.1M	1.4M	1.4M	1.5M
Other Liab	3.9M	4.4M	4.3M	4.0M	4.5M	4.8M
Net Tangible Assets	19.1M	16.4M	30.9M	28.0M	32.2M	18.4M
Other Assets	762K	625K	723K	497K	571.6K	600.1K
Retained Earnings Total Equity	(121.9M)	(141.8M)	(169.0M)	(185.5M)	(166.9M)	(158.6M)
Property Plant Equipment	4.7M	3.2M	7.4M	6.3M	7.3M	7.6M
Capital Surpluse	142.3M	158.2M	200.6M	214.1M	246.2M	258.5M
Capital Lease Obligations	1.7M	1.6M	4.7M	4.3M	3.3M	1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Chromadex Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromadex Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromadex Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromadex Corp Stock:

How To Invest In Chromadex

Details

Is Chromadex Stock a good investment?

Details

What is Chromadex Corp's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.02

Revenue Per Share

1.215

Quarterly Revenue Growth

0.312

Return On Assets

0.0051

Return On Equity

0.0482

The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Chromadex Net Receivables vs Other Current Liab Analysis

Net Receivables vs Other Current Liab

Net Receivables vs Other Current Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Other Current Liab

Chromadex Corp fundamental ratios Correlations

Chromadex Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Chromadex Corp fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Current Liabilities
Common Stock	+ 0.99	Common Stock Total Equity
Other Stockholder Equity	+ 0.96	Total Current Liabilities
Total Current Assets	+ 0.96	Cash
Total Current Assets	+ 0.96	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Liab	- 0.98	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Net Debt	- 0.95	Total Stockholder Equity